Sign In
28 Jun 2013 09:46
28 June 2013
Immunodiagnostic Systems Holdings plc (the "Company")
Additional Listing
Application has today been made to AIM for admission of 133,446 new Ordinary Shares of 2 pence each in the Company ("Shares"). These Shares, which will rank pari passu in all respects with the existing shares in issue, have today been allotted pursuant to the exercise of options under the Company's Approved and Unapproved Share Option Schemes.
Admission is expected to become effective on 4 July 2013. Following admission to trading of the Shares, the Company will have 28,870,361 Ordinary Shares of 2 pence each in issue.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 5190660 |
Patrik Dahlen, Chief Executive Officer | |
Chris Yates, Finance Director | |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel | |
Dr Vijay Barathan | |
FTI Consulting | Tel : +44 (0)207 831 3113 |
Ben Atwell | |
Simon Conway | |
Mo Noonan |
About Immunodiagnostic Systems Holdings PLC
The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.
Follow the stocks
